Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | MC4R | P32245 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | MC1R | Q01726 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20994284 | 0.98 | HRH3 (0.54) | HRH3MC4RALDH1A1MC5RMC3R | |
| SCHEMBL6310150 | 0.85 | MC4R (0.54) | MC4R | |
| SCHEMBL6310157 | 0.85 | MC4R (0.54) | MC4R | |
| SCHEMBL6310147 | 0.85 | MC4R (0.54) | MC4R | |
| SCHEMBL7899722 | 0.85 | RORC (0.43) | HRH3MC4RSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL1970756 | 0.85 | ALDH1A1 (0.46) | HRH3ALDH1A1CCR5 | |
| SCHEMBL1920938 | 0.82 | MC4R (0.62) | HRH3MC4RMC5RMC3RMC1R | |
| SCHEMBL9137609 | 0.81 | MEN1 (0.49) | ALDH1A1 | |
| SCHEMBL8783095 | 0.81 | MEN1 (0.49) | ALDH1A1 | |
| SCHEMBL20994294 | 0.81 | HRH3 (0.49) | HRH3MC4RSLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563074-B | Piperazine derivatives | 安斯泰来制药株式会社 | 2021-09-28 | — | — | CN | disclosed |
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018016458-A1 | PIPERAZINE DERIVATIVE | アステラス製薬株式会社 | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710988-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | HRH3 221/4885MC4R 2/4885ALDH1A1 2792/4885 |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | GPR4, MC4R, TRPC4 | HRH3 221/4885MC4R 2/4885ALDH1A1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.